deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 3-arm NCT03502733

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab

Sponsor: National Cancer Institute (NCI)

Conditions Lymphoma Metastatic Malignant Solid Neoplasm Recurrent Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm
Interventions Biopsy Procedure Biospecimen Collection Computed Tomography Copanlisib Echocardiography Test Ipilimumab Magnetic Resonance Imaging Nivolumab
Updated 40 times since 2018 Last updated: Mar 12, 2026 Started: Aug 14, 2018 Primary completion: Jul 1, 2026 Completion: Jul 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03502733, this PHASE1 trial focuses on Lymphoma and Metastatic Malignant Solid Neoplasm and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 40 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2018 – ~Jul 2018 · 2 months · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~May 2025 · 4 months · monthly snapshot~May 2025 – ~Jul 2025 · 2 months · monthly snapshot~Jul 2025 – ~Oct 2025 · 3 months · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

40 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2026 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Jan 2026 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1

  4. Oct 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1

▶ Show 35 earlier versions

  1. May 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1

  6. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  7. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

  8. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1

  9. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1

  10. Oct 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

  11. Aug 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1

  12. May 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1

  13. Mar 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE1

  14. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1

  15. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1

  16. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  17. May 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

  18. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE1

  19. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  20. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

    Status: Suspended → Recruiting

  21. Mar 2021 — Apr 2021 [monthly]

    Suspended PHASE1

    Status: Recruiting → Suspended

  22. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  23. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1

  24. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  25. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  26. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  27. Mar 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  28. Aug 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  29. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  30. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE1

  31. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  32. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  33. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  34. Jul 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE1

  35. May 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations